Through the secondment of Business Development Managers in the participating centres Transvac aims to find an effective way to manage biomedical research alliances across the European continent and generate an active portfolio of projects with high potential for creating knowledge and value which will be actively managed. Specifically it aims to develop a pipeline of portfolio projects that are actively managed and supported between the centres classified as:
Effort will be focused on regenerative therapies and research in musculo-skeletal, cardiological and neurological disorders, utilising the expertise and insights of the participants in cell therapies, biopharmaceuticals and biomaterial/polymer and nano-based biopharmaceutical delivery to generate an early stage to pre-clinical/clinical phase I pipeline of projects.
Significant effort will be dedicated to the inclusion of SME’s in the applied industrial projects, as partners, customers for the intellectual property with the long-term aim of out-licensing the inventions to large industry.
Partners in the project are:
Fondazione Parco Biomedico San Raffaele (PSB)
Located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region. Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes. The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit.
The Cambridge University Centre for Brain Repair (http://www.brc.cam.ac.uk) contains 14 scientific groups, with research interests in stem cell biology, neurodegeneration, neuroprotection, demyelination, remyelination, axon regeneration, plasticity, neural transplantation, clinical neurology and neurosurgery. In axon regeneration there are two approaches. 1) Axon regeneration after CNS injury is blocked by the formation of a glial scar. The major inhibitory molecules in the glial scar are chondroitin sulphate proteoglycans. The group is studying methods of removing proteoglycans, preventing their synthesis and of modifying the scarring process to prevent the appearance of inhibitory molecules. 2) Adult CNS axons have a very poor intrinsic ability to regenerate their axons after damage which correlates with poor ability to regenerate the growth cone on the end of a cut axon. Growth cone regeneration requires new protein synthesis inside the axon at the site of axotomy. CNS axons lack protein synthesis machinery. Expertise in glial cell biology, axon growth assays, models of brain and spinal cord damage, behavioural assays of spinal cord and brain function, extra cellular matrix biochemistry, axonal transport and protein synthesis, time lapse studies of axon growth. Facilities for animal behavioural studies, lesion models, imaging, neurodegenerative conditions, neural transplantation, stem cell biology, clinical studies in Parkinsons disease, Huntingtons disease, multiple sclerosis, head injury, stroke, rehabilitation.
Dando & Colucci is a management company, specialising in facilitating the development, financing and implementation of life science based innovation ‘clusters’ or science parks by providing tailored insight and management, offering tactical and strategic management to permit correct financial management, leveraging of resources, positioning of clusters/parks on the whole value chain associated with research and development. This stretches from fundamental research through to partnering at the time of real value creation. As such their expertise includes: Internal due diligence to ISO 9001 quality standards; Consortium development and partner recruitment; Fund raising and identification of potential financial backers; Elaboration and negotiation of detailed scientific and development plan; Executive and project management; Consortium operational development and organisation; Resource and technical evaluation; Business development and market analysis; Financial co-ordination and reporting, and Intellectual property management co-ordination.
Centres working with Dando and Colucci LLC managers as part of the project are:
The Institute of Chemical Science and Engineering, EPFL Lausanne, (http://lmrp.epfl.ch/) works in regenerative medicine and pharmacobiology, specialises in chemical engineering polymeric biomaterials, in tissue engineering using stem cells as building blocks. DNA oligos, recombinant proteins and synthetic peptides are designed and expressed to encompass many functions: the ability to be chemically cross linked with an exogenous agent, the ability to be degraded by cell-derived proteases, the ability to support and promote cell migration, and the ability to bind to and slowly release growth factors. These materials are being developed as biosynthetic matrices and nano-vessicles for tissue regeneration. By virtue of the precise design that is possible, one may independently control the rates of cell infiltration, degradation, remodelling, etc., by making changes in the amino acid sequence of the protein polymer. In addition most degradable biomaterials degrade by non-enzymatic hydrolysis. This is in stark contrast to all natural biological degradation, which is precisely regulated by cell-derived proteases. Research facilities include cell biology, molecular biology and peptide and protein chemistry, organic and polymer synthesis, small animal surgery and pharmacology and a fully equipped laboratory for synthesis and characterization of organic polymeric biomaterials, including analytical and preparative HPLC, differential scanning calorimetry, FT-IR spectroscopy, mass spectrometry, rotary evaporators, UV/Vis spectroscopy, automated peptide synthesizer, photo documentation station, preparative FPLC, RT-PCR.
ECRIN (http://www.ecrin.org) is based on the interconnection of national networks of clinical research centres (CRCs) and clinical trial units (CTUs) the European Clinical Research Infrastructures Network (ECRIN) programme is designed to develop an infrastructure allowing for bottom-up harmonisation of support, training, and practice of clinical research. ECRIN aims at providing public or private (mainly biotechnology SME) sponsors with a support for translational research and multicentre clinical studies in Europe. The ECRIN consortium is based on national networks of CRC / CTUs together with the European Forum for Good Clinical Practice (EFGCP).
A major objective of ECRIN consists of stimulating and facilitating the creation of Centres and National Networks, especially in the new member states, for their subsequent connection to the European network. Connecting these national networks within a broad European network will contribute to the critical mass at the European level needed for the implement of European standards and training regarding clinical research. The European Consortium of clinical research infrastructures currently includes 8 networks of CRCs and CTUs, covering 6 European countries representing 260 million citizens (Denmark, France, Germany, Italy, Spain, and Sweden), and constituting 112 different medical centres and hospitals conducting 1500 clinical studies.
Jonathan Dando | alfa
Don't Give the Slightest Chance to Toxic Elements in Medicinal Products
23.03.2018 | Physikalisch-Technische Bundesanstalt (PTB)
North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy